Patent details
EP3795170 Title: PHARMACEUTICAL COMPOSITION COMPRISING CCN5 AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING RETINAL DISEASES
Basic Information
- Publication number:
- EP3795170
- PCT Application Number:
- KR2019006011
- Type:
- European Patent Granted for LU
- Legal Status:
- Unitary Effect Registered
- Application number:
- EP198027658
- PCT Publication Number:
- WO2019221576
- First applicant's nationality:
- Translation Language:
- EPO Publication Language:
- English
- English Title of Invention:
- PHARMACEUTICAL COMPOSITION COMPRISING CCN5 AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING RETINAL DISEASES
- French Title of Invention:
- COMPOSITION PHARMACEUTIQUE COMPRENANT DU CCN5 UTILISÉ COMME INGRÉDIENT EFFICACE POUR LA PRÉVENTION OU LE TRAITEMENT D'UNE MALADIE RÉTINIENNE
- German Title of Invention:
- PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT CCN5 ALS WIRKSTOFF ZUR VORBEUGUNG ODER BEHANDLUNG VON NETZHAUTERKRANKUNGEN
- SPC Number:
Unitary Effect
- Unitary Effect Requested:
- Yes
- Unitary Effect Request Filing Date:
- 09/04/2024
- Link to UPP Register:
- European Patent Register
- Unitary Effect Request Withdrawal Date:
- Unitary Effect Status:
- Unitary Effect Registered
- Unitary Effect Acceptance Decision Date:
- 17/04/2024
- Unitary Effect Rejection Decision Date:
- Unitary Effect Date:
- 20/03/2024
- Unitary Effect Registration Date:
- 17/04/2024
- Unitary Effect Re-establishment of rights Filing Date:
- Unitary Effect Re-establishment of rights EPO Decision :
- Unitary Effect Re-establishment of rights EPO Decision Date:
- Explanatory Text UE:
- Safety Net Request Date:
- Safety Net Decision Date:
- Safety Net Decision Outcome:
- SPC Number:
Dates
- Filing date:
- 16/05/2019
- Grant date:
- 20/03/2024
- EP Publication Date:
- 24/03/2021
- PCT Publication Date:
- 21/11/2019
- Claims Translation Received Date:
- Translations Received Date (B1 EP Publication):
- Translations Received Date (B2 EP Publication):
- Translations Received Date (B3 EP Publication):
- Publication date:
- 20/03/2024
- EP B1 Publication Date:
- 20/03/2024
- EP B2 Publication Date:
- EP B3 Publication Date:
- Lapsed date:
- Expiration date:
- 16/05/2039
- Renunciation date:
- Revocation date:
- Annulment date:
Owner
- From:
- 13/03/2024
- Name:
- Olives Biotherapeutics Inc.
- Address:
- 219-1ho, 123, Cheomdangwagi-ro Buk-gu, Gwangju 61005, Korea (Republic) (KR)
Inventor
1
- Name:
- PARK, Woo Jin
- Address:
- Korea (Republic) (KR)
2
- Name:
- YOON, Aeri
- Address:
- Korea (Republic) (KR)
Priority
- Priority Number:
- 20180056499
- Priority Date:
- 17/05/2018
- Priority Country:
- Korea (Republic) (KR)
Classification
- IPC classification:
- A61K 38/18; A61K 39/395; A61K 31/7105; A61K 31/7088; A61K 35/12; A61K 35/28; A61K 35/30; A61K 35/545; A61K 35/76; A61P 27/02; C07K 16/22; C12N 15/86;
Publication
European Patent Bulletin
1
- Issue number:
- 202412
- Publication date:
- 20/03/2024
- Description:
- Grant (B1)
2
- Issue number:
- 202417
- Publication date:
- 24/04/2024
- Description:
- Application number/publication number of the divisional application (Art. 76) changed
3
- Issue number:
- 202420
- Publication date:
- 15/05/2024
- Description:
- Unitary Effect Request Receipt
4
- Issue number:
- 202421
- Publication date:
- 22/05/2024
- Description:
- Unitary Effect Request Acceptance
Annual Fees
- Annual Fee Due Date:
- Annual Fee Number:
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|